A Phase II/III, Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Oral Controlled-Ileocolonic-Release Nicotinamide (CICR-NAM) for Induction and Maintenance Therapy in Patients With Mild to Moderately Active Ulcerative Colitis
Double-blind, randomised, placebo-controlled phase II / III trial evaluating efficacy and safety of two different doses (2 g/d or 3 g/d) of oral controlled-ileocolonic-release nicotinamide (CICR-NAM) compared to placebo in patients with ulcerative colitis (UC).
The intended therapeutic use of CICR-NAM is to improve intestinal inflammation in adults with UC by topically increasing nicotinamide supply in the ileocolonic region and thus favourably influencing the composition of intestinal microbiota
Real-World observational study on the health situation (QoL) and the psychosocial well-being of patients with ulcerative colitis under filgotinib therapy in the long-term course
Effectiveness of Ustekinumab in Induction and Maintenance Therapy of ulcerative colitis (RUN-UC) - RUN-UC
100 项与 Ced Service GmbH 相关的临床结果
0 项与 Ced Service GmbH 相关的专利（医药）
100 项与 Ced Service GmbH 相关的药物交易
100 项与 Ced Service GmbH 相关的转化医学
